Overview
Data provided by Nasdaq. Minimum 15 minutes delayed.
February 14, 2019
NantHealth® and NantOmics to Reveal New Research Demonstrating Importance of Examining RNA Expression and Individual Biomarkers in Cancer Testing
Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium SAN FRANCISCO & CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 14, 2019-- Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American Society of Clinical Oncology’s (ASCO) Genitourinary Cancers Symposium this week. The two companies, respective leaders in molecular profiling research and g...
February 12, 2019
NantHealth® Debuts Multiple Connected Care Initiatives at HIMSS
Collaboration with Leading Kidney Care Vendors, Intelligent Health and Connected Care Showcased CULVER CITY, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Feb. 12, 2019-- NantHealth, Inc. (NASDAQ: NH), a leader in connected care solutions, will unveil a series of new initiatives designed to improve patient outcomes and provider satisfaction at the 2019 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition ...
January 04, 2019
NantCell Announces New Celgene Investment
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene's Investment to $105M in NantCell Valued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials in 15 Indications for Registration IntentDeep Pipeline Of 28 Unique Molecules With 14 First in Human Studies in Over 1,000 Patients to DateLos Angeles, CA, January 4, 2019 – NantCell and its founder Dr. Patrick Soon-Shiong announced...
There are currently no events scheduled. |